Key Highlights
• Avalon GloboCare sold Series F convertible preferred stock and 200,000 common shares for a total of $400,000.
• Each preferred share has a $1,000 stated value and may convert into common stock at $0.50 per share, subject to a 4.99% ownership cap.
• Mandatory redemption will occur in four monthly installments of 25% each at a price of 125% of the stated value.
Avalon GloboCare Corp. (NASDAQ: ALBT) entered into a Securities Purchase Agreement (.1) on June 30 2026 to sell Series F Convertible Preferred Stock together with additional common shares to accredited investor Allen O. Cage Jr. The closing took place on July 2 2026, with the company receiving $400,000 in cash.
Deal Structure
Under the agreement the company issued 5,000 shares of Series F Convertible Preferred Stock. Each of those shares carries a par value of $0.0001 and a stated value of $1,000.00. In addition, the investor received 200,000 shares of the company’s common stock, each also bearing a par value of $0.0001.
The aggregate purchase price for the preferred and common securities amounted to $400,000.00.
Conversion Mechanics
The preferred shares are convertible into common stock at a fixed conversion price of $0.50 per share. Conversion may occur after the requisite shareholder approval and is limited by a beneficial‑ownership restriction of 4.99%, ensuring that the holder cannot exceed the prescribed percentage of the company’s outstanding common equity. The conversion ratio will adjust for stock splits, cash dividends and similar corporate events.
Each redemption is priced at 125% of the stated value per share, providing the holder with a cash return that exceeds the original valuation. The schedule is structured to occur on a monthly basis following the closing, without reference to specific calendar dates.
Ownership Constraints
The 4.99% ownership limitation functions throughout the life of the preferred stock and any subsequent conversion into common shares. This provision helps maintain the existing balance of control among existing shareholders while allowing the investor to benefit from the conversion feature.
Recent Equity Activity
On June 29 2026, the Company issued 150,000 restricted common shares in connection with services rendered. On July 1 2026, the Company issued 200,000 additional common shares in exchange for a waiver of certain rights. The following day, July 2 2026, an aggregate of 750,000 restricted shares were issued to further consultants.
Because the offering was confined to accredited investors, registration with the SEC was not required, allowing the transaction to be completed swiftly.
Sector Context
Avalon GloboCare operates within the biotechnology sector, where capital‑intensive research and development programs often rely on preferred equity to fund clinical trials and regulatory milestones. Convertible preferred structures such as the Series F issuance give investors participation upside while giving the company flexible financing options that do not dilute existing shareholders until conversion is exercised. This financing aligns with typical industry practice of pairing preferred capital with conversion rights and redemption features that protect both investor and issuer interests.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...